论文部分内容阅读
目的观察胃复安对偏头痛的疗效和安全性。方法采用随机双盲安慰剂对照法,选择偏头痛患者312例,治疗组156例,对照组156例,两组临床资料相似(P>0.05)。结果治疗组单次口服胃复安20mg,2h及4h后对偏头痛有效率为54.5%和59.6%;对照组分别为23.1%和27.6%,治疗组显著优于对照组(p<0.01)。对伴随症状尤其是恶心、呕吐,治疗组有较好的疗效,无一例不良反应发生。结论单次口服胃复安20mg对偏头痛有较显著的治疗作用,且无不良反应发生。
Objective To observe the efficacy and safety of metoclopram on migraine. Methods A randomized, double-blind, placebo-controlled study was conducted in 312 migraine patients, 156 patients in the treatment group and 156 in the control group. The clinical data of the two groups were similar (P> 0.05). Results In the treatment group, the single oral metoclopramide 20mg, 2h and 4h after the effective rate of migraine on 54.5% and 59.6%; control group were 23.1% and 27.6%, the treatment group was significantly better than the control group (p <0.01). On the accompanying symptoms, especially nausea, vomiting, the treatment group has a good effect, no adverse reactions occurred. Conclusion A single oral metoclopramide 20mg has a significant therapeutic effect on migraine without any adverse reaction.